Literature DB >> 26624964

Early initiation of low-level parenteral dextrose induces an accelerated diabetic phenotype in septic C57BL/6J mice.

Srikanth Singamsetty1, Faraaz Ali Shah1, Lanping Guo1, Yoshio Watanabe1, Sherie McDonald1, Rohit Sharma2, Yingze Zhang1, Laura C Alonso2, Christopher P O'Donnell1, Bryan J McVerry1.   

Abstract

Development of hyperglycemia during sepsis is associated with increased morbidity and mortality. Nutritional support is common practice in the intensive care unit, but the metabolic effects are not well understood. The purpose of this study is to determine the effect of early low-level calorie provision on the development of hyperglycemia in a clinically relevant murine model of sepsis. C57BL/6J mice underwent femoral arterial and venous catheterization followed by cecal ligation and puncture (CLP) or sham surgery and low-dose intravenous dextrose or saline infusion. Blood glucose, plasma insulin, and cytokines were measured after 24 h. Additional septic mice underwent hyperinsulinemic-euglycemic clamps or received intravenous insulin concurrent with dextrose to determine whole-body insulin sensitivity and test the efficacy of insulin to reverse hyperglycemia. Neither dextrose infusion nor CLP alone induced hyperglycemia. Early initiation of low-level dextrose in septic mice produced a variable glycemic response: 49% maintained euglycemia (blood glucose < 200) and 27% developed severe hyperglycemia (blood glucose ≥ 600). Hyperglycemia was associated with increased inflammation and reduced insulin secretion and sensitivity compared with control mice or CLP mice maintaining euglycemia. Insulin prevented the progression to severe hyperglycemia but was ineffective in reestablishing glycemic control once hyperglycemia had developed. In conclusion, early initiation of clinically relevant low-level dextrose (∼ 20% daily caloric requirements) precipitated hyperglycemia akin to an acute diabetic phenotype in septic mice characterized by decreased insulin sensitivity, decreased insulin secretion, and an increased inflammatory response.

Entities:  

Keywords:  critical illness; dextrose; hyperglycemia; hyperglycémie; maladie grave; mouse; nutrition; sepsie; sepsis; souris

Mesh:

Substances:

Year:  2015        PMID: 26624964      PMCID: PMC4756584          DOI: 10.1139/apnm-2015-0213

Source DB:  PubMed          Journal:  Appl Physiol Nutr Metab        ISSN: 1715-5312            Impact factor:   2.665


  27 in total

1.  Intensive insulin therapy in critically ill patients.

Authors:  G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity.

Authors:  Nao Iiyori; Laura C Alonso; Jianguo Li; Mark H Sanders; Adolfo Garcia-Ocana; Robert M O'Doherty; Vsevolod Y Polotsky; Christopher P O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2007-02-01       Impact factor: 21.405

3.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

4.  Glucose infusion in mice: a new model to induce beta-cell replication.

Authors:  Laura C Alonso; Takuya Yokoe; Pili Zhang; Donald K Scott; Seung K Kim; Christopher P O'Donnell; Adolfo Garcia-Ocaña
Journal:  Diabetes       Date:  2007-03-30       Impact factor: 9.461

5.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

6.  Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis.

Authors:  C J Fisher; S M Opal; S F Lowry; J C Sadoff; J F LaBrecque; H C Donovan; J L Lookabaugh; J Lemke; J P Pribble; S C Stromatt
Journal:  Circ Shock       Date:  1994-09

7.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors:  C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

8.  The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia.

Authors:  Nadine S Sauter; Fabienne T Schulthess; Ryan Galasso; Lawrence W Castellani; Kathrin Maedler
Journal:  Endocrinology       Date:  2008-01-31       Impact factor: 4.736

9.  Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression.

Authors:  V K Mehta; W Hao; B M Brooks-Worrell; J P Palmer
Journal:  Eur J Endocrinol       Date:  1994-02       Impact factor: 6.664

10.  Intensive insulin therapy and pentastarch resuscitation in severe sepsis.

Authors:  Frank M Brunkhorst; Christoph Engel; Frank Bloos; Andreas Meier-Hellmann; Max Ragaller; Norbert Weiler; Onnen Moerer; Matthias Gruendling; Michael Oppert; Stefan Grond; Derk Olthoff; Ulrich Jaschinski; Stefan John; Rolf Rossaint; Tobias Welte; Martin Schaefer; Peter Kern; Evelyn Kuhnt; Michael Kiehntopf; Christiane Hartog; Charles Natanson; Markus Loeffler; Konrad Reinhart
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

View more
  6 in total

1.  Glucose homeostasis in two degrees of sepsis lethality induced by caecum ligation and puncture in mice.

Authors:  Francielle B D Ferreira; Cristiane Dos Santos; Maciel A Bruxel; Everson A Nunes; Fernando Spiller; Alex Rafacho
Journal:  Int J Exp Pathol       Date:  2017-12-11       Impact factor: 1.925

2.  Stimulation of the endogenous incretin glucose-dependent insulinotropic peptide by enteral dextrose improves glucose homeostasis and inflammation in murine endotoxemia.

Authors:  Faraaz Ali Shah; Srikanth Singamsetty; Lanping Guo; Byron W Chuan; Sherie McDonald; Bryce A Cooper; Brett J O'Donnell; Darko Stefanovski; Burton Wice; Yingze Zhang; Christopher P O'Donnell; Bryan J McVerry
Journal:  Transl Res       Date:  2017-11-21       Impact factor: 7.012

Review 3.  Pancreatic Islet Responses to Metabolic Trauma.

Authors:  Susan J Burke; Michael D Karlstad; J Jason Collier
Journal:  Shock       Date:  2016-09       Impact factor: 3.454

Review 4.  Cross-Talk Between Iron and Glucose Metabolism in the Establishment of Disease Tolerance.

Authors:  Ana Rita Carlos; Sebastian Weis; Miguel P Soares
Journal:  Front Immunol       Date:  2018-10-30       Impact factor: 7.561

5.  Association of the systemic host immune response with acute hyperglycemia in mechanically ventilated septic patients.

Authors:  Nauman Farooq; Byron Chuan; Hussain Mahmud; Samar R El Khoudary; Seyed Mehdi Nouraie; John Evankovich; Libing Yang; Daniel Dunlap; William Bain; Georgios Kitsios; Yingze Zhang; Christopher P O'Donnell; Bryan J McVerry; Faraaz Ali Shah
Journal:  PLoS One       Date:  2021-03-23       Impact factor: 3.240

6.  Physiologic Effects of Exogenous Dextrose in Murine Klebsiella pneumoniae Sepsis Vary by Route of Provision.

Authors:  Byron Chuan; Lanping Guo; Bryce Cooper; Sagar Rawal; Teresa Gallego-Martin; Yingze Zhang; Bryan J McVerry; Christopher P O'Donnell; Faraaz Ali Shah
Journal:  Nutrients       Date:  2020-09-23       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.